GLPwatch
Papers (10404)
Page 82 of 174, ranked by citation count.
- Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells.
- Dulaglutide and renal protection in type 2 diabetes.
- Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
- Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12).
- Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression.
- Repression of sterol regulatory element-binding protein 1-c is involved in the protective effects of exendin-4 in pancreatic β-cell line.
- Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
- Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
- Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
- Exenatide improves glucocorticoid-induced glucose intolerance in mice.
- Exendin-4 inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis.
- Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin.
- Liraglutide-induced acute pancreatitis.
- Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide.
- Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.
- An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks.
- The design of the liraglutide clinical trial programme.
- Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity.
- Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis.
- PDGF Facilitates Direct Lineage Reprogramming of Hepatocytes to Functional β-Like Cells Induced by Pdx1 and Ngn3.
- Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.
- Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
- Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.
- Principal components analysis on genes related to inflammasome complex and microglial activation in the hypothalamus of obese mice treated with semaglutide (GLP-1 analog).
- Storage and Utilization of Glycogen by Mouse Liver during Adaptation to Nutritional Changes Are GLP-1 and PASK Dependent.
- Liraglutide treatment effects on rat ovarian and uterine tissues.
- Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea.
- The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
- Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice.
- Cardiovascular disease leads to a new algorithm for diabetes treatment.
- Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R.
- Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.
- In vitro performance of composition-equivalent PLGA microspheres encapsulating exenatide acetate by solvent evaporation.
- Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
- Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
- Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.
- A case report of allergy to exenatide.
- Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
- Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway.
- Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
- Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret.
- Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.
- Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
- The GLP-1 receptor is expressed <i>in vivo</i> by human metastatic prostate cancer.
- Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
- Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events.
- Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.
- Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1.
- Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
- Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.
- Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
- Evidence-Based Cardiovascular Risk Management in Diabetes.
- Tirzepatide: Clinical review of the "twincretin" injectable.
- Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
- Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.
- Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
- Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.
- Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
- Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
- Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.